Editorial: The Analysis of Nanovesicles, Biomaterials and Chemical Compounds: Assisting the Promotion of Angiogenesis and Enhancing Tissue Engineering Strategies

Vincenzo Lionetti 1*, Niketa Sareen 1,2 and Sanjiv Dhingra 2*

1 Unit of Translational Critical Care Medicine, Institute of Life Sciences, Scuola Superiore Sant’Anna, Pisa, Italy, 2 Regenerative Medicine Program, Department of Physiology and Pathophysiology, Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, University of Manitoba, Winnipeg, MB, Canada

Keywords: cardiovascular disease, stem cells, cardiac repair, extracellular vesicles, nanovesicles, nanomaterials, tissue engineering

Editorial on the Research Topic

The Analysis of Nanovesicles, Biomaterials and Chemical Compounds: Assisting the Promotion of Angiogenesis and Enhancing Tissue Engineering Strategies

Heart disease remains the leading cause of morbidity and mortality worldwide. The loss of functional cardiomyocytes after an ischemic or non-ischemic injury leads to permanent damage to the heart muscle as cardiomyocytes are terminally differentiated and are not able to replace the damaged cells. The currently available pharmacological therapies are able to provide temporary relief and improve life span of cardiac patients. However, these interventions are not able to offer permanent solution to the problem. Thus, there is an urgent need for new and more effective approaches that can provide permanent treatment options for the heart disease. In this regard stem cell-based therapies have emerged as promising solution (Figure 1) (1, 2). Stem cells have the ability to differentiate into cardiomyocytes and replenish lost cardiac cells due to cardiac injury. In fact in different experimental animal models of heart failure, transplantation of stem cells led to improvement in cardiac function and the mechanisms of cardiac repair were dependent upon the type of stem cells employed (3). Some pre-clinical studies suggested that pluripotent cells such as embryonic stem cells and induced pluripotent stem cells (iPSC) promote cardiac repair by differentiating into beating cardiomyocytes in the heart after implantation (4, 5). On the other hand, bone marrow derived and adipose tissue derived mesenchymal stem cells (MSCs) are reported to promote cardiac repair through paracrine mechanisms (1, 6). MSCs are known to secrete several growth factors, angiogenic, antiapoptotic factors and immunosuppressive molecules. These paracrine factors are responsible for cardiac repair by promoting angiogenesis in the infarcted heart, limiting cardiomyocyte loss, and suppressing inflammation caused by immune cell infiltration. Although the therapeutic efficacy of MSCs has been clearly demonstrated in different animal models and no side effects were observed in patients after transplantation of MSCs in the heart, only very few phase III clinical trials using MSCs have shown encouraging results (7). Indeed, beneficial effects of transplanted MSCs in terms of cardiac repair were very short lived, and major reason for this poor performance of MSCs was limited survival of transplanted cells in the injured heart. Therefore, the strategies that can improve the survival of transplanted stem
cells in the heart could be of immense therapeutic value. In this regard, investigators working in the field have suggested different approaches to improve survival of implanted MSCs in the heart (8). Some of the studies reported that preconditioning of MSCs with chemical compounds such as hyaluronan mixed ester of butyric and retinoic acid (9, 10) and overexpression of different cell survival proteins such as AKT and ERK ½ can improve survival of implanted cells in the heart (11). Several other studies reported that microRNA (miRNA) mediated approaches are also able to promote survival of transplanted cells. Role of multiple miRNAs in survival of MSCs has been studied and reported by different investigators (12). Some of the miRNAs which have been reported to promote MSCs survival include miR-1, miR-210, miR-378, miR-34a, miR-21, miR-23a, miR-503 (13). One such study in this special issue highlights the role of miR-377 in mediating cardiomyocyte death. In this study Henderson et al. evaluated the effect of miR-377 on DOX induced cardiotoxicity in mouse model and reported that inhibiting miR-377 results in changes in pathways regulating cell proliferation, inflammation, apoptosis and differentiation.

Recently, biomaterials based approaches are also being explored to improve survival of transplanted stem cells in the heart. In this regard, hydrogels and nanoparticles mediated delivery of stem cells has shown significant promise (Figure 1). In past, some of the common natural and synthetic hydrogels used in MSC therapy include collagen, alginate, hyaluronic acid, chitosan or poly glycerol sebacate derivatives (14). The hydrogels and nanoparticles can also be tagged with soluble factors such as prostaglandin E₂ (PGE₂) and fibroblast growth factor (FGF) that promote survival of stem cells in the myocardium (1, 15). In addition to this, these biomaterials can be used as a delivery vehicle for transporting drugs or biochemical agents to the damaged myocardium for beneficial effects. Alvi et al., discuss this aspect of nanoparticles, microspheres and hydrogels in modulating positive effects by employing different fabrication and formulation strategies. They also highlight the clinical trials being carried out using this set of biomaterials for improving cardiac condition. Furthermore, hydrogels made of extra cellular matrix (ECM) based biomaterials can act as bulking agents and are also reported to prevent inflammatory response in heart due to their ECM like structure (16).

The nanoparticles also offer several advantages due to their physical properties including size, charge, shape, surface area and functional groups (17, 18). The metal-based nanoparticles,
quantum dots and magnetic nanoparticles are most commonly used for stem cells and drug delivery. Gokce et al., review the applications of currently used 2D materials for cardiac regeneration. Their report provides a deeper understanding of these biomaterials in terms of their immunomodulatory properties and inducing cardioprotective effects. Additionally, biomaterials are also reported to aid in tracking of transplanted stem cells due to their inherent fluorescence abilities (19).

In addition to stem cells as source of cell therapy, in some of the recent studies, stem and progenitor cells derived extracellular vesicles (EVs) or exosomes have garnered a lot of attention by acting as cell-free systems for cardiac repair following myocardial injury (20). A detailed review on the role of stem cells derived exosomes has been compiled by Jayaraman et al. in this special issue. The authors have provided insights about different aspects of exosome biogenesis, storage and preservation with emphasis on their role in mediating the positive effects in cardiac ailments. The study highlights major advantages of using exosomes over stem cells for cardiac therapy; along with some of the key points to consider before large scale application of exosomes involving isolation and storage. The EVs are reported to exhibit beneficial effects by acting as reservoirs of paracrine factors that are produced by MSCs and progenitor cells. In addition to this, EVs are also reported to act as cargos to deliver important biomolecules such as microRNAs, metabolites, amino acids, lipids, DNA, proteins or even drugs to target tissues (21, 22). Pant et al., discuss the therapeutic role of non-coding RNAs (ncRNA) in exosomes. This review covers the role of ncRNA contained in MSC derived exosomes in cardiac, bone and cartilage tissue regeneration. They have also highlighted miRNA mediated applications of exosomes in neurodegenerative disorders as well as in cancer. Based on the type of cells EVs are derived from, these vesicles can differ in their contents, thus, resulting in different effects at the injection site. This phenomenon is demonstrated in research conducted by Ranjan et al., where exosomes sourced from myofibroblasts were responsible for induction of apoptosis and reduced proliferation of endothelial cells. Moreover, these exosome treated endothelial cells also exhibit reduced angiogenesis and cell migration.

In addition to this, conventional cardiovascular drugs such as ticagrelor may modulate the release of exosomes from cardiac progenitor cells (23). Multiple reports have also suggested that EVs or exosomes promote cardiac repair by preventing apoptosis, inflammation and oxidative stress, as well as by improving angiogenesis and cardiac remodeling (Jayaraman et al.) (24, 25). These aspects of EV mediated cardioprotection have been discussed in this special issue by Liu et al. The review covers the role of EVs derived from multiple sources in treating cardiac pathologies. The authors also discuss various strategies to modify EVs for better therapeutic effects. However, besides preventing negative remodeling, EVs can also act as important markers of cardiac pathology by acting as intercellular communicators of immune cells. This aspect of EVs has been elaborated in the article by Jadli et al. The authors discuss important aspect of EV mediated signaling in cardiac pathologies like atherosclerosis, HF, ischemic heart disease and various forms of cardiomyopathies.

Some of the recent studies have suggested that delivery of EVs using biomaterials prevents their wash out at the site of injection (26). Furthermore, the application of a combination of biomaterials and exosomes is also reported to suppress elevated immune response, promote tissue regeneration and wound healing (27). Therefore, a combination of different approaches may be a better approach for future regenerative strategies for cardiac repair (26). However, there is a need to conduct more extensive studies in clinically relevant animal models of heart failure using these new approaches.

The goal of this focused issue was to bring together state-of-the-art original research and review articles from experts in the field of cardiovascular disease, stem cells, nanomaterials, extracellular nanovesicles and microRNAs, with special focus on translational aspects of these approaches. Our hope is that in future the readers would benefit from the articles in this special issue and come up with more effective state-of-the-art tools to repair injured myocardium in patients.

**AUTHOR CONTRIBUTIONS**

The study was conceptualized and designed by VL and SD. VL, NS, and SD carried out literature search, and prepared manuscript and figure. All authors have read and approved the final manuscript.

**FUNDING**

This work was supported by funding from the Canadian Institutes of Health Research to SD and by funding from Fondazione Pisa (Italy; Etherna: prog. n. 161/16) to VL. NS was supported by Go for IT Project of Fondazione CRUI (Italy; CardioNEX).

**REFERENCES**

1. Dhingra S, Li P, Huang X-P, Guo J, Wu J, Mihic A, et al. Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function. *Circulation*. (2013) 128:569–78. doi: 10.1161/CIRCULATIONAHA.112.003234

2. Abu-El-Rub E, Sequiera GL, Sareen N, Yan W, Moudgil M, Sabbir MG, et al. Hypoxia-induced 26S proteasome dysfunction increases immunogenicity of mesenchymal stem cells. *Cell Death Dis.* (2019) 10:1–17. doi: 10.1038/s41419-019-1359-x

3. Yan W, Abu-El-Rub E, Saravananan S, Kirshenbaum LA, Arora RC, Dhingra S. Inflammation in myocardial injury: mesenchymal stem cells as potential immunomodulators. *Am J Physiol-Heart Circ Physiol.* (2019) 317:H213–25. doi: 10.1152/ajpheart.00065.2019

4. Oikonomopoulos A, Kitani T, Wu JC. Pluripotent stem cell-derived cardiomyocytes as a platform for cell therapy applications: progress and hurdles for clinical translation. *Mol Ther.* (2018) 26:1624–34. doi: 10.1016/j.ymthe.2018.02.026

5. Batalov I, Feinberg AW. Differentiation of cardiomyocytes from human pluripotent stem cells using monolayer culture. *Biomark Insights*. (2015) 10:71–6. doi: 10.4137/BMI.S20050
6. Ammar HI, Sequiera GL, Nashed MB, Ammar RI, Gabr HM, Elsayed HE, et al. Comparison of adipose tissue- and bone marrow-derived mesenchymal stem cells for alleviating doxorubicin-induced cardiac dysfunction in diabetic rats. *Stem Cell Res Ther.* (2015) 6:148. doi: 10.1186/s13287-015-0142-x

7. Banerjee MN, Bolli R, Hare JM. Clinical studies of cell therapy in cardiovascular medicine. *Circ. Res.* (2018) 123:266–87. doi: 10.1161/CIRCRESAHA.118.311217

8. Sareen N, Abu-El-Rub E, Ammar HI, Yaw, Sequiera GL, ShamsEldeen AM, et al. Hypoxia-induced downregulation of cyclooxygenase 2 leads to the loss of immunoprivilege of allogeneic mesenchymal stem cells. *FASEB J.* (2020) 34:15236–51. doi: 10.1096/fj.202001788R

9. Ventura C, Canioni S, Bianchi F, Lionetti V, Cavallini C, Scarlata I, et al. Hyaluronan mixed esters of butyric and retinoic acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts *. J Biol Chem.* (2007) 282:14243–52. doi: 10.1074/jbc.M609350200

10. Simionionic A, Campan M, Lionetti V, Marinelli M, Aquaro GD, Cavallini C, et al. Placental stem cells pre-treated with a hyaluronan mixed ester of butyric and retinoic acid to cure infarcted pig hearts: a multimodal study. *Cardiovasc Res.* (2011) 90:546–56. doi: 10.1093/cvr/cvr018

11. Golpanian S, Wolf A, Hatzistergos KE, Hare JM. Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue. *Physiol Rev.* (2016) 96:1127–68. doi: 10.1152/physrev.00019.2015

12. Nie Y, Han B-M, Liu X-B, Yang J-Y, Wang F, Cong X-F, et al. Identification of microRNAs involved in hypoxia- and serum deprivation-induced apoptosis in mesenchymal stem cells. *Int J Biol Sci.* (2011) 7:762–8. doi: 10.7150/ijbs.7.762

13. Collino F, Bruno S, Lindoso RS, Camussi G. miRNA expression in mesenchymal stem cells. *Curr Pathobiol Rep.* (2014) 2:101–7. doi: 10.1007/s40139-014-0045-z

14. Hasan A, Khattab A, Islam MA, Hwej KA, Zeitouny J, Waters R, et al. Injectable hydrogels for cardiac tissue repair after myocardial infarction. *Adv Sci.* (2015) 2:1500122. doi: 10.1002/advs.201500122

15. Li L, Chen X, Wang WE, Zeng C. How to improve the survival of transplanted mesenchymal stem cell in ischemic heart? *Stem Cells Int.* (2016) 2016:9682757. doi: 10.1155/2016/9682757

16. Smagul S, Kim Y, Smagulova A, Razjiyeva K, Nurkesh A, Saparov A. Biomaterials loaded with growth factors/cytokines and stem cells for cardiac tissue regeneration. *Int J Mol Sci.* (2020) 21:E5952. doi: 10.3390/ijms21175952

17. Sun Y, Lu Y, Yin L, Liu Z. The roles of nanoparticles in stem cell-based therapy for cardiovascular disease. *Front Bioeng Biotechnol.* (2020) 8:947. doi: 10.3389/fbioe.2020.00947

18. Saravanan S, Sareen N, Abu-El-Rub E, Ashour H, Sequiera GL, Ammar HJ, et al. Graphene oxide-gold nanosheets containing chitosan scaffold improves ventricular contractility and function after implantation into infarcted heart. *Sci Rep.* (2018) 8:15069. doi: 10.1038/s41598-018-33144-0

19. Rafieerad A, Yan W, Sequiera GL, Sareen N, Abu-El-Rub E, Moudgil M, et al. Application of Ti3C2 MXene quantum dots for immunomodulation and regenerative medicine. *Adv Healthc Mater.* (2019) 8:1900569. doi: 10.1002/adhm.201900569

20. Wagner KT, Radisic M. A new role for extracellular vesicles in cardiac tissue engineering and regenerative medicine. *Adv NanoBimed Res.* (2021) 21:100047. doi: 10.1002/anbr.202100047

21. Kanada M, Bachmann MH, Hardy JW, Frimannsson DO, Bronsart L, Wang A, et al. Differential fates of biomolecules delivered to target cells via extracellular vesicles. *Proc Natl Acad Sci USA.* (2015) 112:E1433–42. doi: 10.1073/pnas.1418401112

22. Stranford DM, Leonard JN. Chapter five - delivery of biomolecules via extracellular vesicles: a budding therapeutic strategy. In: Friedmann T, Dunlap JC, Goodwin SF, editors. *Advances in Genetics.* San Diego, CA: Academic Press (2017). p. 155–75. doi: 10.1016/ba.adgen.2017.08.002

23. Casieri V, Matteucci M, Pasanisi EM, Papa A, Barile L, Frischa-Danielson R, et al. Ticagrelor enhances release of anti-hypoxic cardiac progenitor cell-derived exosomes through increasing cell proliferation in vitro. *Sci Rep.* (2020) 10:2494. doi: 10.1038/s41598-020-59225-7

24. Fu S, Zhang Y, Li Y, Luo L, Zhao Y, Yao Y. Extracellular vesicles in cardiovascular diseases. *Cell Death Discov.* (2020) 6:1–9. doi: 10.1038/s41420-020-00305-y

25. Barile L, Lionetti V, Cervio E, Matteucci M, Gherghiceanu M, Popescu LM, et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. *Cardiovasc Res.* (2014) 103:330–41. doi: 10.1093/cvr/cvu167

26. Pezzana C, Agnely F, Bochet A, Siepmann J, Menasché P. Extracellular vesicles and biomaterial design: new therapies for cardiac repair. *Trends Mol Med.* (2021) 27:231–47. doi: 10.1016/j.molmed.2020.10.006

27. Golchin A, Shams F, Baeriswyl P, Ranbarvan K, Kiani S, Sarkhosh-Inanlo R, et al. Combination therapy of stem cell-derived exosomes and biomaterials in the wound healing. *Stem Cell Rep Rev.* (2022). doi: 10.1007/s12015-021-10309-5. [Epub ahead of print].

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lionetti, Sareen and Dhingra. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.